|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
<b>Conclusion:</b> HK1 and HK2 expression are redundant in tumors; either can provide sufficient aerobic glycolysis for tumor growth; despite a reduction in <sup>18</sup>F-FDG PET signal.
|
29880505 |
2018 |
|
Tumor Progression
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
<b>Results:</b> Neither cell proliferation in culture nor xenograft tumor progression are inhibited by HK2 knockdown or knockout in cancer cells that express HK1 and HK2.
|
29880505 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
(1) mutations in the coding regions of the HKII gene are unlikely to be major determinants in the development of insulin resistance and familial NIDDM; although (2) the influence of the codon 142 mutation in combination with other abnormalities of the insulin-signalling pathway on insulin action remain to be addressed.
|
8721778 |
1996 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Cancer Cell Line Encyclopedia data were analyzed for HK1 and HK2 expression.
|
29880505 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Cancer Cell Line Encyclopedia data were analyzed for HK1 and HK2 expression.
|
29880505 |
2018 |
|
Diabetes
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Diabetes reduced <i>Slc2a4</i>/GLUT4 and <i>Hk2</i>/HK2 expression (50-77%), upregulated miR-29b-3p and miR-29c-3p (50-100%), and downregulated miR-93-5p, miR-150-5p, miR-199a-5p, miR-345-3p, and miR-532-3p (~30%) expression.
|
30258406 |
2018 |
|
Diabetes Mellitus
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Diabetes reduced <i>Slc2a4</i>/GLUT4 and <i>Hk2</i>/HK2 expression (50-77%), upregulated miR-29b-3p and miR-29c-3p (50-100%), and downregulated miR-93-5p, miR-150-5p, miR-199a-5p, miR-345-3p, and miR-532-3p (~30%) expression.
|
30258406 |
2018 |
|
Liver neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-inducible factor 1 alpha and its significance.
|
14672622 |
2004 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy.
|
19101634 |
2009 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy.
|
19101634 |
2009 |
|
Metastatic malignant neoplasm to brain
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Hexokinase 2 (HK2) was also of interest because of its increased expression in brain metastases.
|
19723875 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme.
|
21242296 |
2011 |
|
Glioblastoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme.
|
21242296 |
2011 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hexokinase II represents a potential new therapeutic target in this malignancy.
|
21279699 |
2012 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Hexokinase II represents a potential new therapeutic target in this malignancy.
|
21279699 |
2012 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hexokinase II is a key enzyme in the glycolytic pathway and CD133+ human hepatoma cells possess cancer stem cell-like properties.
|
21909686 |
2012 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Hexokinase II is a key enzyme in the glycolytic pathway and CD133+ human hepatoma cells possess cancer stem cell-like properties.
|
21909686 |
2012 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer.
|
23911236 |
2013 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer.
|
23911236 |
2013 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hexokinase 2 (HK2) has been identified as an oncogene in some malignant diseases such as breast cancer and ovarian cancer.
|
26802651 |
2016 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hexokinase 2 (HK2) has been identified as an oncogene in some malignant diseases such as breast cancer and ovarian cancer.
|
26802651 |
2016 |
|
Carcinoma, Ovarian Epithelial
|
0.090 |
Biomarker
|
disease |
BEFREE |
Hexokinase 2 (HK2) has been identified as an oncogene in some malignant diseases such as breast cancer and ovarian cancer.
|
26802651 |
2016 |
|
ovarian neoplasm
|
0.060 |
Biomarker
|
disease |
BEFREE |
Hexokinase 2 (HK2) has been identified as an oncogene in some malignant diseases such as breast cancer and ovarian cancer.
|
26802651 |
2016 |
|
Malignant neoplasm of ovary
|
0.060 |
Biomarker
|
disease |
BEFREE |
Hexokinase 2 (HK2) has been identified as an oncogene in some malignant diseases such as breast cancer and ovarian cancer.
|
26802651 |
2016 |
|
Neoplasm Metastasis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Hexokinase 2 is a determinant of neuroblastoma metastasis.
|
26986252 |
2016 |